An LCD is a determination by a Medicare Administrative Contractor, or MAC, whether to cover a particular service on a MAC-wide, basis. A MAC processes Medicare Part A and Part B claims for a defined ...

As part of the transition to the new administration, CMS is reviewing its coverage policies for skin substitute products.

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

The average plasma fibrinogen level was 681 ± 160 mg/dL, exceeding the normal range. Fibrinogen levels increased with ulcer severity, measuring 503.51 mg/dL for Wagner Grade 2, 623.45 mg/dL for Grade ...

CMS issued the following statement on Local Coverage Determination for certain skin substitute grafts: “As part of the transition to a new ...

Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.

After three years of development, a smart insole designed by researchers at the University of Malta is showing promising ...

Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers." "We are extremely pleased ...